Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

02.07.20	Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation d (GlobeNewswire)
01.07.20	Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case (GlobeNewswire)
29.06.20	Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options (GlobeNewswire)
26.06.20	Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile (GlobeNewswire)
26.06.20	Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps (GlobeNewswire)
25.06.20	Novartis Resolves Legacy FCPA Investigations (GlobeNewswire)
17.06.20	Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis (GlobeNewswire)
11.06.20	US FDA approves updated Novartis Beovu® label, to include additional safety information (GlobeNewswire)
05.06.20	Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma (GlobeNewswire)
04.06.20	Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis (GlobeNewswire)
02.06.20	Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis (GlobeNewswire)
29.05.20	Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery (GlobeNewswire)
29.05.20	Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation (GlobeNewswire)
27.05.20	Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease (GlobeNewswire)
27.05.20	Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS) (GlobeNewswire)
19.05.20	AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA) (GlobeNewswire)
14.05.20	Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms (GlobeNewswire)
06.05.20	Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14 (GlobeNewswire)
01.05.20	Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma (GlobeNewswire)
29.04.20	Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum (GlobeNewswire)
28.04.20	Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19 (GlobeNewswire)
28.04.20	Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen (GlobeNewswire)
22.04.20	Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease (GlobeNewswire)
22.04.20	Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma (GlobeNewswire)
21.04.20	Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS) (GlobeNewswire)
20.04.20	Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients (GlobeNewswire)
20.04.20	Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye” (GlobeNewswire)
16.04.20	Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine (GlobeNewswire)
02.04.20	Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program (GlobeNewswire)
02.04.20	Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo (GlobeNewswire)
28.03.20	Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment (GlobeNewswire)
27.03.20	Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum (GlobeNewswire)
27.03.20	AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA) (GlobeNewswire)
26.03.20	Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation (GlobeNewswire)
24.03.20	Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing (GlobeNewswire)
24.03.20	AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2 (GlobeNewswire)
20.03.20	Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response (GlobeNewswire)
19.03.20	Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA) (GlobeNewswire)
18.03.20	Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy (GlobeNewswire)
02.03.20	Sandoz Resolves Generic Drug Antitrust Investigation in the U.S. (GlobeNewswire)
28.02.20	Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut (GlobeNewswire)
28.02.20	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
24.02.20	Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS) (GlobeNewswire)
17.02.20	Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide (GlobeNewswire)
11.02.20	Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review (GlobeNewswire)
31.01.20	Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines (GlobeNewswire)
29.01.20	Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019 (GlobeNewswire)
29.01.20	Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe (GlobeNewswire)
20.01.20	Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease (GlobeNewswire)
16.01.20	Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

19:37		TELL me! - der Schweizer Trading Podcast: Ausblick 2025: stabil bis positiv - Dividenden Titel: Coca-Cola, Sanofi und Evonik
18:01		Minuszeichen in New York: Dow Jones präsentiert sich mittags leichter
18:01		NASDAQ Composite-Handel aktuell: NASDAQ Composite legt zu
17:58		STOXX-Handel: STOXX 50 zum Handelsende im Aufwind
17:58		SPI-Handel aktuell: SPI steigt zum Ende des Dienstagshandels
17:58		Freundlicher Handel in Frankfurt: TecDAX letztendlich freundlich
17:58		Euro STOXX 50-Handel aktuell: Euro STOXX 50 zum Ende des Dienstagshandels mit Gewinnen